{
    "Trade/Device Name(s)": [
        "Alinity c Tricyclic Antidepressants Reagent Kit"
    ],
    "Submitter Information": "Microgenics Corporation Thermo Fisher Scientific",
    "510(k) Number": "K231020",
    "Predicate Device Reference 510(k) Number(s)": [
        "K213875"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LFH"
    ],
    "Summary Letter Date": "October 11, 2023",
    "Summary Letter Received Date": "October 13, 2023",
    "Submission Date": "November 17, 2023",
    "Regulation Number(s)": [
        "21 CFR 862.3910"
    ],
    "Regulation Name(s)": [
        "Tricyclic Antidepressant Drugs Test System"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Tricyclic antidepressants",
        "Nortriptyline",
        "Amitriptyline",
        "Imipramine",
        "Desipramine",
        "Clomipramine",
        "Doxepin",
        "Trimipramine",
        "Protriptyline",
        "Dosulepin",
        "Lofepramine",
        "Opipramol",
        "N-Desmethyltrimipramine",
        "Norclomipramine",
        "Nordoxepin"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "K2 EDTA tube",
        "K3 EDTA tube",
        "Lithium heparin tube",
        "Sodium citrate tube",
        "Potassium oxalate tube",
        "Sodium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Alinity c system"
    ],
    "Method(s)/Technology(ies)": [
        "Homogeneous enzyme immunoassay"
    ],
    "Methodologies": [
        "Automated clinical chemistry assay",
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Reagent",
        "Assay",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for Alinity c Tricyclic Antidepressants Reagent Kit using homogeneous enzyme immunoassay for detection of tricyclic antidepressants in serum and plasma on the Alinity c system.",
    "Indications for Use Summary": "Homogeneous enzyme immunoassay intended for qualitative and/or semiquantitative determination of tricyclic antidepressants in human serum or plasma at a 300 ng/mL cutoff on the Alinity c system in patients suspected of drug overdose; for in vitro diagnostic use only.",
    "fda_folder": "Toxicology"
}